Gathering information on maternal immunization readiness in Bangladesh, Ghana, Kenya, Mozambique, and Nepal: Applying a WHO checklist
Ranju Baral Sophia Knudson Iracema Barros Patience Cofie Patience Dapaah Sadaf Khan Sandeep Kumar Kamran Mehedi Lauren Newhouse Elkanah Otiang Rosemond Owusu Clint Pecenka Melanie Picolo Judite Pinto Diana Quelhas Satyabrata Routray Surendra Uranw Jessica A. Fleming a Center for Vaccine Innovation and Access,PATH,Seattle,USAb Primary Health Care,PATH,Seattle,USAc Primary Health Care,PATH,Maputo,Mozambiqued Primary Health Care,PATH,Accra,Ghanae Medical Devices and Health Technologies,PATH,Accra,Ghanaf India Country Program,PATH,New Delhi,Indiag Center for Vaccine Innovation and Access,PATH,Dhaka,Bangladeshh Epidemic Preparedness and Response,PATH,Nairobi,Kenyai Independent Consultant,Accra,Ghanaj Independent Consultant,Maputo,Mozambiquek B.P. Koirala Institute of Health Sciences (BPKIHS),Dharan,NepalRanju Baral is a senior health economist at PATH. In this role,she designs and conducts economic evaluation studies including costing,health impact modeling,cost-effectiveness analysis,budget impact analysis,and demand forecasting for vaccines and vaccine delivery. Her current work focuses on disease and public health interventions and integration of noble interventions such as RSV,and maternal immunization to the public health programs for better impact. She works closely with global and country partners to generate health economic evidence informing policy decisions.
DOI: https://doi.org/10.1080/21645515.2024.2437258
2024-12-18
Human Vaccines & Immunotherapeutics
Abstract:New respiratory syncytial virus (RSV) maternal vaccines have begun roll out in some countries, with efforts in progress to broaden access worldwide and shorten the timeline to access for low- and middle-income countries (LMICs). Prior to new maternal immunization (MI) introductions, countries will need to evaluate their capacity and readiness for successful introduction. The World Health Organization's Maternal Immunization and Antenatal Care Situation Analysis (MIACSA) project (2016–2019) developed a checklist for countries to self-evaluate their capacity to introduce new maternal vaccines. Here, we report on our use of the MIACSA checklist in Bangladesh, Ghana, Kenya, Mozambique, and Nepal to gather country stakeholders' perceptions of MI readiness and provide additional considerations for implementers when using the checklist to optimize its usefulness.
immunology,biotechnology & applied microbiology